Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGDR2 | Q9Y5Y4 | 11/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | TACR1 | P25103 | 1/20 | 0.44 |
| ▸ | KRAS | P01116 | 3/20 | 0.41 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1757605 | 0.89 | HSD17B10 (0.48) | PTGDR2ALDH1A1MAPT | |
| SCHEMBL1758337 | 0.88 | PTGDR2 (0.49) | PTGDR2ALDH1A1MAPT | |
| SCHEMBL1757420 | 0.88 | PTGDR2 (0.51) | PTGDR2ALDH1A1MAPTLOXL2 | |
| SCHEMBL1757765 | 0.86 | KDM4E (0.49) | PTGDR2ALDH1A1HTT | |
| SCHEMBL1757886 | 0.79 | PTGDR2 (0.80) | PTGDR2MAPT | |
| SCHEMBL1758338 | 0.78 | PTGDR2 (0.50) | PTGDR2ALDH1A1MAPTTACR1KRAS | |
| SCHEMBL1757472 | 0.77 | PTGDR2 (0.81) | PTGDR2 | |
| SCHEMBL1757737 | 0.76 | PTGDR2 (0.70) | PTGDR2 | |
| SCHEMBL1757774 | 0.75 | PTGDR2 (0.69) | PTGDR2 | |
| SCHEMBL1757609 | 0.75 | MAPT (0.48) | PTGDR2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | WYETH, LLC (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105509-A1 | INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS | HRH2, CRHR2, CRHR1 | PTGDR2 13/4885ALDH1A1 1069/4885HTT 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.